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Abstract Proprotein convertase subtilisin/kexin type 9
(PCSK9) is a circulating enzyme of hepatic origin that plays a
key role in LDL receptor turnover. Genetic studies have con-
firmed that individuals with gain-of-function PCSK9mutations
have increased PCSK9 activity, elevated LDL-cholesterol
levels and a severe form of familial hypercholesterolaemia.
Those with variants leading to reduced PCSK9 have lower
LDL-cholesterol levels and a reduced risk of coronary heart
disease, and this has led to the development of various strategies
aimed at reducing circulating PCSK9. Monoclonal antibodies
to PCSK9, given every 2–4 weeks by subcutaneous injection,
have been shown to reduce LDL-cholesterol by 50–60% com-
pared with placebo in individuals with and without diabetes.
PCSK9 inhibition also reduces lipoprotein(a), an atherogenic
lipid particle, by around 20–30%. Major cardiovascular out-
come trials for two agents, evolocumab and alirocumab, are
expected to report from 2017. These trials involve over
45,000 participants and are likely to include about 15,000 indi-
viduals with diabetes. PCSK9-binding adnectins have been
employed as an alternative method of removing circulating
PCSK9. Small interfering RNA targeting messenger RNA for
PCSK9, which acts by reducing hepatic production of PCSK9,
is also under investigation. These agents may only need to be
given by subcutaneous injection once every 4–6 months.
Ongoing trials will determine whether anti-PCSK9 antibody
therapy safely reduces cardiovascular risk, although high cost
may limit its use. Development of PCSK9-lowering technolo-
gies cheaper than monoclonal antibodies will be necessary for
large numbers of individuals to benefit from this approach to
lowering cholesterol.
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Abbreviations
ACC American College of Cardiology
CVD Cardiovascular disease
FDA Food and Drug Administration
FH Familial hypercholesterolaemia
FOURIER Further Cardiovascular Outcomes Research
with PCSK9 Inhibition in Subjects with
Elevated Risk
PCSK9 Proprotein convertase subtilisin/kexin type 9
siRNA Small interfering RNA
SPIRE Studies of PCSK9 Inhibition and the Reduction
of Vascular Events
Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibi-
tors are powerful LDL-cholesterol-lowering medications cur-
rently being investigated inmajor cardiovascular outcome trials.
In this review, we discuss the following topics: the biology of
PCSK9; studies confirming the causal relationship between
PCSK9 and cardiovascular disease (CVD); the various classes
of PCSK9 inhibitors at different stages of investigation; the
efficacy (in people with and without diabetes where data are
available) and safety of PCSK9 inhibitors and their potential
position in clinical practice.
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Hepatic expression of the LDL receptor is a major deter-
minant of circulating LDL-cholesterol [1]. Individuals
with heterozygous familial hypercholesterolaemia (FH)
exhibit either reduced expression of LDL receptors or re-
duced binding of apolipoprotein B to the LDL receptors,
with a resultant increase in circulating LDL-cholesterol
and elevated cardiovascular risk [2]. Statins increase hepatic
LDL receptor expression, consequent to low intracellular cho-
lesterol levels. The resulting enhanced uptake of LDL from
the circulation and reduction in blood LDL-cholesterol con-
centration reduces cardiovascular risk in people with and
without diabetes [3, 4].
PCSK9 belongs to a family of proteases called proprotein
convertases, which catalyse the conversion of secretory precur-
sors into active products [5]. It is a circulating protein of hepatic
origin, expressed from a genetic locus on chromosome arm
1p32.3, which is intimately involved in hepatic LDL receptor
turnover [6]. Under normal conditions, when PCSK9 binds to
the LDL receptor and is internalised, lysosomal degradation
follows and there is no recirculation of that LDL receptor to
the hepatocyte surface (Fig. 1). Thus, PCSK9 reduces LDL
receptor expression by the liver, resulting in reduced uptake
of LDL from the circulation and, consequently, higher circulat-
ing LDL-cholesterol levels [7].
The potential importance of PCSK9 to LDL-cholesterol
homeostasis and cardiovascular risk was identified in var-
ious seminal genetic studies. In 2003, Abifadel and col-
leagues reported that two kindreds with premature CVD
and apparently unexplained autosomal dominant hyper-
cholesterolaemia, based on known FH genetic mutations,
were affected by gain-of-function mutations in the PCSK9
gene leading to increased activity of PCSK9 and marked
hypercholesterolaemia [8]. PCSK9 activity has since been
confirmed as a key determinant of LDL-cholesterol levels
and mutations in PCSK9 have been confirmed as the
cause of a very rare, but particularly severe, form of FH.
Complementary information came from studies of indi-
viduals with loss-of-function PCSK9 mutations and low
PCSK9 act ivi ty. In the Atherosclerosis Risk in
Communities Study, about 1 in 40 black participants
(n = 3363) carried a nonsense mutation (PCSK9142X or
PCSK9679X) in the PCSK9 gene [9]. This genotype was
associated with 28% lower LDL-cholesterol levels and a
HR for CHD of 0.11 (95% CI 0.02, 0.81), admittedly with
wide CIs given the small number of coronary events.
Similarly, of 9524 white individuals, about 1 in 30 had a
heterozygous sequence variation (PCSK946L) in PCSK9
that was associated with 15% lower LDL-cholesterol
levels and a halving in the risk of CHD (adjusted HR


















Fig. 1 The effect of PCSK9 on LDL receptor turnover and mechanisms
of action of different PCSK9 inhibitors. (a) In the absence of PCSK9, the
LDL receptor is recirculated to the cell surface after carrying LDL
into lysosomes. (b) PCSK9 is produced by the liver and enters the
circulation. (c) When PCSK9 binds to the LDL receptor, it undergoes
lysosomal degradation and is not recirculated to the cell surface, thereby
preventing uptake of LDL (dashed lines). (d) Monoclonal antibodies to
PCSK9 and adnectins act by binding to PCSK9, thereby removing it from
the circulation and preventing binding of PCSK9 to the LDL receptor
(dashed line). (e) siRNAs act by degrading mRNA, thereby reducing
PCSK9 release to the circulation (dashed line). ER, endoplasmic reticu-
lum; mAb, monoclonal antibody
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subsequently been replicated in larger studies [10].
Furthermore, individuals with compound heterozygous
loss-of-function mutations in PCSK9 and, consequently,
no circulating PCSK9 and very low LDL-cholesterol
levels appear to suffer no obvious clinical disadvantage
from the lack of PCSK9 [11].
Available inhibitors of PCSK9
The aim of therapy with PCSK9 inhibitors is to reduce circu-
lating PCSK9 levels, thereby increasing hepatic LDL receptor
expression and lowering circulating LDL-cholesterol levels.
Current therapeutic approaches involve either the binding of
circulating PCSK9 (monoclonal antibodies and modified
binding proteins) or reducing the hepatic production of the
protein (small interfering RNAs [siRNAs]) (Fig. 1).
Therapies currently under investigation are given by
subcutaneous injection; we are not aware of any ongo-
ing clinical trials of an oral PCSK9-lowering prepara-
tion, although attempts have been made to develop oral-
ly administered agents.
Monoclonal antibodies to PCSK9 Monoclonal antibodies
targeted at PCSK9 are the best-developed strategy for low-
ering PCSK9. Two agents, evolocumab and alirocumab,
are currently under investigation in major Phase 3 clinical
trial programmes (Table 1) [12, 13]. Data for bococizumab
are also included in Table 1 despite the recent discontinu-
ation of clinical trials with this agent due to attenuation of
LDL-cholesterol lowering over time and comparatively
higher levels of immunogenicity and greater frequency of
injection-site reactions [14, 15]. Evolocumab and
alirocumab are fully human antibodies while bococizumab
is a partially humanised antibody. Notably, at least one-
third of participants in the major trials have diabetes. The
first of these trials is expected to report in 2017. Research
programmes for some PCSK9 monoclonal antibodies have
been discontinued in Phase 2 (e.g. RG-7652) while others
have yet to enter Phase 3 (e.g. LY3015014) [16]. These
agents are given by subcutaneous injection, typically once
every 2–4 weeks [12, 13, 15] although some are now being
tested at intervals of 8 weeks [16]. Patients require training
on how to administer the therapy. The drug needs to be
stored in a refrigerator and then warmed to room temper-
ature before injection.
Modified binding-protein inhibitors of PCSK9 (adnectins)
While the inhibition of PCSK9 by small molecules has
proven challenging, PCSK9-binding adnectin-based
polypeptides have been developed [17]. Adnectins are
compact proteins with branched-out loops, derived from
human fibronectin tenth type III domain, which can be
modified to bind a target with strong affinity. Data are
available from Phase 1 trials in 64 healthy participants
to whom single ascending doses of BMS-962476 were
given intravenously or subcutaneously and participants
were followed for up to 6 weeks [18]. LDL-cholesterol
reductions of up to 48% occurred between days 4 and
14 post dose. There are no ongoing clinical trials of this
agent at present.
Targeting PCSK9 with siRNA siRNA has been developed
which acts within the hepatocyte to inhibit PCSK9 synthesis
by degrading the mRNA of the intended protein [19]. In a
Phase 1 single-escalating-dose placebo-controlled clinical trial
conducted in 32 healthy volunteers with LDL-cholesterol
≥3.0 mmol/l, ALN-PCS was given intravenously [20]. The
highest dose studied (0.4 mg/kg) lowered LDL-cholesterol
by 40% on average. In subsequent Phase 1 studies various
doses, both single and multiple, have been given subcutane-
ously. A potential benefit of this agent’s mechanism of action
lies in its prolonged effect on LDL-cholesterol. Single doses
of 300 mg and 500 mg lowered LDL-cholesterol levels by
about 50% at 12 weeks [21]. This difference, when compared
with placebo, was largely preserved (at approximately 40%) at
6 months post dose, suggesting that a dose need only be ad-
ministered once every 4–6 months. Separate results for indi-
viduals with diabetes are not yet available.
Effects of monoclonal antibodies to PCSK9 in people
with and without diabetes
Monoclonal antibodies to PCSK9 have typically yielded re-
ductions in LDL-cholesterol levels of 50–60% compared with
placebo at the doses tested in the major Phase 3 trials [22].
Table 2 provides examples of the lipid-modifying effects of
evolocumab, alirocumab and bococizumab from selected tri-
als. Maximal reduction of LDL-cholesterol levels is achieved
when all PCSK9 is bound and, therefore, further increases in
drug dose have no further effects (apart from modestly
prolonging the duration of action). Unlike treatment with
statins, which vary in LDL-cholesterol-lowering efficacy,
these PCSK9 inhibitors are expected to provide similar max-
imal effect. In addition, it is well recognised that PCSK9 in-
hibition leads to a reduction in levels of lipoprotein(a), an
atherogenic lipid particle causally implicated in CVD [23],
of about 20–30% [24, 25]. Statins have no such effect. The
reduction in lipoprotein(a) levels is not fully understood and
kinetic lipid studies are required to elucidate the mechanism
behind this.
See the Text box for a summary of the effects of antibodies
to PCSK9.
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Lipids and C-reactive protein Reductions in atherogenic
lipids have been similar in trial participants with and without
diabetes in whom circulating PCSK9 levels are also similar. A
pooled analysis of data from three 12 week evolocumab trials
with 2532 participants (413 with diabetes, 2119 without dia-
betes) was published recently [26]. In individuals with and
without diabetes, respectively, when compared with placebo,
evolocumab reduced levels of LDL-cholesterol by 60% and
66%, non-HDL-cholesterol by 55% and 58%, total cholesterol
by 38% and 40%, triacylglycerols by 23% and 17% and
lipoprotein(a) by 31% and 29%. HDL-cholesterol levels rose
by 8% and 7% in participants with and without diabetes, re-
spectively. There was no evidence of heterogeneity between
diabetic and non-diabetic participants [26]. Furthermore, in a
post hoc analysis of the DESCARTES trial, the effect of
evolocumab (vs placebo) on LDL-cholesterol at 52 weeks
was similar among participants with diabetes (n=120; 51%
reduction), impaired fasting glucose (n=293; 59% reduction),
the metabolic syndrome (n=289; 55% reduction) and those
without these conditions (393; 58% reduction) [27]. Similarly,
the 1 year results of two controlled open-label extension trials
of evolocumab (vs standard care) showed that the reduction in
LDL-cholesterol and triacylglycerol levels was comparable in
those with and without diabetes [28].
For alirocumab, 24 week data are available from the Long-
term Safety and Tolerability of Alirocumab in High
Cardiovascular Risk Patients with Hypercholesterolemia Not
Adequately Controlled with Their Lipid Modifying Therapy
(ODYSSEY LONG TERM) trial [29]. Participants (2341 par-
ticipants: 832 with diabetes, 1509 without diabetes) at elevat-
ed cardiovascular risk were randomised to receive alirocumab
or placebo. Changes in LDL-cholesterol (59% vs 63% reduc-
tion in those with vs without diabetes, respectively), triacyl-
glycerol (19% vs 17% reduction) andHDL-cholesterol (3% vs
5% increase) levels, comparedwith placebo,were similar in those
with and without diabetes. We are not aware of data for partici-
pants with diabetes from the bococizumab programme [30].
One feature of statin therapy is that while starting
doses typically yield relatively large reductions in LDL-
cholesterol (e.g. 22%, 32%, 40% and 49% for a 10 mg daily
dose of pravastatin, simvastatin, atorvastatin and rosuvastatin,
respectively [12]), doubling the dose only provides a further
6% reduction in LDL-cholesterol on average, apparently driven
by increased production of PCSK9 in response to statin therapy
[13]. It is apparent that the introduction of PCSK9-lowering
treatment provides similar, or probably greater, proportional
reductions in LDL-cholesterol levels when an individual is on
a statin compared with no statin therapy [30].
An interesting finding in these Phase 2 studies has been that
although statins moderately lower C-reactive protein levels
and have a modest anti-inflammatory effect [31, 32], PCSK9
inhibitors appear to have no effect on C-reactive protein [33].
Cardiovascular outcomes Conclusive data regarding the ef-
fect of monoclonal antibodies on cardiovascular events are
expected from the major outcome trials (Table 1) [12, 13].
Given the well-established effect of PCSK9 inhibitors on
LDL-cholesterol and the confirmed causal relationship be-
tween LDL-cholesterol levels and CVD [34], results from
these major cardiovascular outcome trials are among the most
eagerly awaited in the field of cardiovascular and metabolic
medicine. While preliminary data from smaller, shorter tri-
als have suggested substantial cardiovascular benefit (as
much as a halving of major cardiovascular events) [35,
36], these results are based on only around 130 cardiovas-
cular events, indicating that they should be interpreted with
caution. Recently, the GLobal Assessment of Plaque
reGression with a PCSK9 antibOdy as Measured by
intraVascular Ultrasound (GLAGOV) trial has shown that
  Effects of therapeutic inhibition of PCSK9
• Inhibition of PCSK9 by monoclonal antibodies, adnectins or siRNA reduces LDL-cholesterol levels
by approximately 40–60% compared with placebo
• Unlike statins, PCSK9 inhibitors reduce lipoprotein(a) levels by approximately 20% but appear to
have no effect on C-reactive protein
• Recently published data have demonstrated a reduction in coronary plaque volume with a
monoclonal PCSK9 antibody compared with placebo
• Robust data for cardiovascular outcomes will be provided by major Phase 3 clinical trials in 2017–
2018
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evolocumab reduced coronary plaque volume (vs placebo)
when added to statin therapy. [37].
Safety profile of monoclonal antibodies to PCSK9
The clinical trial programmes for evolocumab and alirocumab
have raised few concerns thus far and adherence to
randomised active treatment and placebo has been similar.
As noted above, individuals with no measurable circulating
PCSK9 and low LDL-cholesterol levels appear to suffer no
clinical disadvantage [11]. Putative side effects and the avail-
able evidence are summarised below.
Injection-site reactions A reaction at the site of injection has
typically been reported in around 5% of trial participants, with
little difference between placebo- and PCSK9-inhibitor-treated
patients [36, 38].
Anti-drug antibodies Anti-drug antibodies have not been de-
tected in evolocumab-treated patients [39] and have been found
in only a small number of alirocumab-treated patients [40], with
no apparent detrimental effect on the LDL-cholesterol-lowering
efficacy of the drug. Development of such antibodies may ex-
plain the diminishing LDL-cholesterol-lowering effect seenwith
bococizumab that led to the termination of its development [14].
Neurocognitive events In 2014, the US Food and Drug
Administration (FDA) mandated that ongoing cardiovascular
outcome trials of PCSK9 inhibitors must include detailed eval-
uation of neurocognitive events, at least in a subset of partici-
pants. Two studies (two pooled open-label extension trials of
evolocumab; one placebo-controlled trial of alirocumab)
showed that a greater number of participants receiving a
PCSK9 inhibitor reported neurocognitive adverse events than
control participants [35, 36]. However, the open-label design of
the evolocumab studies makes this finding difficult to interpret
and the blinded alirocumab study included only 22 patients
with neurocognitive adverse events. More information will
come from the EBBINGHAUS trial, a substudy within the
Further Cardiovascular Outcomes Research with PCSK9
Inhibition in Subjects with Elevated Risk (FOURIER) trial,
in which measures of cognitive function are the primary
outcome [41]. Importantly, lowering LDL-cholesterol by
1–1.5 mmol/l in the statin trials is not associated with any
deterioration in measures of cognition [42].
New-onset diabetes and glycaemic control Statins appear to
have a small diabetogenic effect and low LDL-cholesterol
levels may be causally linked to higher diabetes risk [34,
43]. This prompted the listing of new-onset diabetes as a
pre-specified outcome in major trials of PCSK9 inhibitors.
The first major genetic polymorphism study of PCSK9
variants and their association with diabetes has suggested that
diabetes risk is 15–20% higher in the context of a 1 mmol/l
genetically predicted reduction in LDL-cholesterol [44].
However, data from evolocumab and alirocumab clinical trials
appear reassuring thus far [27, 45]: although based on small
numbers of new-onset diabetes events, even if a diabetogenic
effect is found it is likely to be small.
Very low concentrations of LDL-cholesterol The combina-
tion of intensive statin therapy and PCSK9 inhibition (as used in
the cardiovascular endpoint trials) will achieve lower LDL-
cholesterol concentrations than have previously been possible.
Dose-reduction strategies to address this concern have been tried
in participants whose LDL-cholesterol falls below predefined
thresholds (with similar steps being taken in an equal number
of placebo-treated patients to maintain blinding). The knowl-
edge that free-living individuals with genetically determined
low or very low levels of LDL-cholesterol, based on PCSK9
mutations, appear to suffer no clinical disadvantage [11, 46] is
reassuring but data from large-scale trials are required to address
this theoretical concern.
PCSK9 inhibitors: their potential place in clinical
practice
Statins are cheap, safe and effective [4] and are likely to remain
the mainstay of lipid-lowering treatment for individuals with and
without diabetes, particularly the 300million diabetic individuals
in low- or middle-income countries. Currently, evolocumab and
alirocumab are both approved by the FDA and the European
Medicines Agency for use in some people with FH and in indi-
viduals with pre-existing CVD who are on maximal-tolerated
statin dose and who require additional lipid-lowering therapy.
Recently, an American College of Cardiologists (ACC) Expert
Consensus Decision Pathway recommended consideration of
PCSK9 inhibitors, after maximising statin therapy and attention
to adherence, in several high-risk groups including those with
prior CVD and diabetes who have not achieved a ≥50% reduc-
tion in LDL-cholesterol and possibly in such individuals who
have not achieved a non-HDL-cholesterol level of <2.6 mmol/l
[47]. However, recommendations for their use in many coun-
tries will require Phase 3 studies to demonstrate not only that
these agents are efficacious and safe but also that they are cost
effective. Table 3 illustrates the likely absolute benefit that
would be expected with PCSK9 inhibitors, assuming that the
reduction in cardiovascular events achieved for each mmol/l
reduction in LDL-cholesterol is the same as that observed with
statins [4]. In the majority of individuals already on statin ther-
apy, the absolute reduction in LDL-cholesterol with a PCSK9
inhibitor will be moderate, at around 1 mmol/l. This would be
expected to result in a reduction in major vascular events of
around one-quarter. Whether this potential benefit outweighs
386 Diabetologia (2017) 60:381–389
the cost, treatment burden and any risks for people with diabe-
tes will depend heavily on the cardiovascular risk of an individ-
ual. In the UK, rates of hospital admission for CVD (based on a
broad definition of International Classification of Diseases cod-
ing) in people with diabetes, but no prior CVD, are around 1.5–
2.5% per year depending on ethnicity [48], and these rates
continue to fall [49]. For primary prevention of CVD in people
with diabetes receiving a statin, the absolute benefit of PCSK9
inhibitors is estimated to be around 13–19 people who will
avoid major cardiovascular events (per 1000 people treated
for 5 years, assuming an annual event rate of 1–1.5%;
Table 3). This benefit would be highly unlikely to justify the
substantial cost (approximately $14,000 per year in the USA
and £4000 per year in the UK) and inconvenience of treatment.
As outlined in the ACC guidelines mentioned above, the
likely role for monoclonal antibody PCSK9 inhibitors will,
apart from for patients with FH, be in secondary prevention
particularly among those at highest risk such as those with
diabetes in whom the annual cardiovascular event rate might
be around 3–4% per year [50]. In such individuals, the addition
of a PCSK9 inhibitor to statin treatment might result in around
38–50 people avoiding suffering a cardiovascular event for ev-
ery 1000 people treated for 5 years (Table 3). However, at
current UK prices this would still cost almost £400,000 for each
person protected from suffering a major cardiovascular event
(not taking into account the prevention of recurrent CVD events
or resulting heart failure). The challenge for the companies
developing anti-PCSK9 antibodies and other PCSK9 inhibitors
is therefore to produce effective agents at lower cost.
Conclusions
The results from the keenly awaited FOURIER and ODYSSEY
Outcomes trials will soon establish whether lowering LDL-
cholesterol via inhibition of PCSK9 produces the expected
reductions in major cardiovascular events. Equally important,
however, will be establishing whether these treatments are asso-
ciated with any hazard and identifying populations at sufficiently
high vascular risk for this treatment to be cost effective.
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